The prevalence of CTNNB1 mutations in primary aldosteronism and consequences for clinical outcomes
Vin‐Cent Wu(National Taiwan University Hospital), Kwan‐Dun Wu(National Taiwan University Hospital)
Cited by 93
Related Papers
GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease
|Nature Communications|2024|65
Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohort
|The Lancet Diabetes & Endocrinology|2025|53
Impact of SGLT2 inhibitors on patient outcomes: a network meta-analysis
|Cardiovascular Diabetology|2023|39